1. Introduction
===============

Increasing evidence for the major role of host genetics has accumulated in research on inter-individual variation in susceptibility to infectious diseases, particularly since a HLA allele was found to be susceptible to leprosy (1980) from early case-control studies of unrelated individuals with disease and unaffected controls. Host genetic studies on infectious diseases have identified a number of novel gene associations that implied the molecular pathways involved in disease pathogenesis \[[@B1]\].

Over the last decade since the completion of the human genome project, host genetic studies have robustly progressed using single nucleotide polymorphism (SNP) analysis, DNA sequencing, DNA microarrays, and cytogenetic methods. Recently, the technological development of high throughput genotyping has provided a powerful tool to examine the genetic basis of disease through Genome-Wide Association Studies (GWASs). This approach has considerably increased the number of known genes associated with major diseases \[[@B2]\].

Dengue infections (DI) are a serious cause of morbidity and mortality in tropical and subtropical areas of the world including Southeast and South Asia, Central and South America, and the Caribbean \[[@B3]\]. The disease is caused by dengue virus (DV), a *flavivirus* transmitted to humans mainly by infected *Aedes aegypti* mosquitoes \[[@B4]\]. Infection by any of the 4 serotypes of DV, DV-1, -2, -3, and -4, may result in a wide clinical spectrum, ranging from asymptomatic to fever (DF), haemorrhagic fever (DHF) and shock syndrome (DSS), the life threatening complications being characterized mainly by plasma leakage. Recently, WHO suggested a new classification which separates severe dengue patients from those with non-severe dengue \[[@B5]\]. To be consistent with the publications reviewed, we use WHO 1997 criteria in this paper.

The postulated factors excerting an influence on manifestations can be divided into viral and host factors.

*Viral factors:* Higher blood viral load was detected in DHF patients in comparison to DF patients \[[@B6]\]. DV-2 had a larger pleural effusion index than the other virus serotypes in Thailand \[[@B6]\] and clearly related to the severe clinical forms in a study in Vietnam \[[@B7]\]. Imported to America, this genotype is thought to be the cause of the appearance of DHF in this region \[[@B8]\], providing additional proof for the higher virulence of the Asian DV-2 genotype.

*Host factors:* Plasma leakage happens often occurs at day 4--6 of fever when the viremia has already declined \[[@B9]\], revealing the role of host immunopathological mechanisms in disease severity. Both dengue-virus-infected monocytes with Antibody-Dependent Enhancement (ADE) phenomenon \[[@B10]\], and activated specific T lymphocytes are responsible for the rapidly increased levels of cytokines in DHF \[[@B11], [@B12]\]. These cytokines, especially TNF-α, IFN-γ, and chemical mediators, including IL-1 and IL-6 from mast cell \[[@B13]\], play a key role in inducing important clinical manifestations of DHF, that is, plasma leakage and shock. However, how the virus-host interaction causes the clinical outcome remains an important question. Epidemiological evidence indicates that host genetic factors are relevant and predispose the DHF/DSS development.

In this review, we summarize the findings from host genetic polymorphism studies concerning human leucocyte antigens, antibody receptors, immune/inflammatory mediators, attachment molecule, cytokines and other factors excerting immunoregulatory effects, as well as the current status of genome-wide association studies. The accumulated evidences, integrated properly, will provide important insights into the pathogenesis of severe dengue and shed light on new prevention and treatment options.

2. Host Genetic Factors Involved in the Clinical Course of Dengue Virus Infection
=================================================================================

2.1 The major histocompatibility complex (MHC)
----------------------------------------------

### a. Human leucocyte antigen (HLA) --class I and class II sub regions

HLA is encoded by the major histocompatibility complex (MHC), located on the chromosome 6 in humans. The genes encoding HLA class I (HLA-A, -B, -C) and class II (HLA-DR, DQ and DP) are the most polymorphic in the human genome \[[@B14]\]. Both class I and II molecules are involved in displaying peptide antigen to host T lymphocytes \[[@B15]\], being the essential recognition elements of acquired and innate immune responses to viruses \[[@B16]\]. However, the interaction between antigenic epitopes and the host immune system varies with the HLA allele involved \[[@B17]\]. Polymorphisms in HLA alleles may correlate with differential T cell profiles that lead to variable anti-viral responses \[[@B18]\]. The host HLA allele profile influenced the reactivity of DV-specific T cells \[[@B19]\] and may be responsible for the immunopathology of DV infection \[[@B20]\]. This is why HLA is the most extensively studied allele regarding the association with severity of DV infection.

Both HLA classes I and II genes were intensively analyzed (Table [1](#T1){ref-type="table"}A, [1](#T1){ref-type="table"}B). As in many genetic studies, the case-control study of HLA association to dengue infection often compares HLA allele frequencies in DF, DHF/DSS patients (each form or combined) with those in healthy controls of the same ethnicity, or by level of disease severity (DHF/DSS vs. DF or controls). A new trend consistent with 2009 WHO criteria can be seen in studies that separate the most severe form, DSS and DHF/DF \[[@B7], [@B21], [@B22], [@B23]\], or even asymptomatic cases \[[@B22], [@B24]\].

With certain HLA alleles, DV serotype could affect the clinical outcome, especially DV-2 in Southeast Asia (SEA), as in the case of B\*52 allele associated with secondary DF only in DV-2 in the Thai population \[[@B25]\], or DRB1\*0901 which particularly protects the development to DSS from DHF in the Kinh ethnic with DV-2 infection \[[@B7]\].

As shown in Table [1](#T1){ref-type="table"}, many HLA class I alleles have been shown to be associated with severe dengue in secondary DI, suggesting the importance of the existing primed memory HLA class I-restricted cross-reactive T cell. This is not always the case, however, as in A\*24 association with primary infections in a Vietnamese study \[[@B7]\]. Meanwhile, HLA class II, especially DRB1 alleles, more likely exerted a protective effect on DI \[[@B7], [@B26], [@B27]\] and disease severity \[[@B26]\]. A better understanding of this protection mechanism may lead to novel preventive and immuno-therapeutic approaches, including vaccines.

### b. HLA-class III sub-region

Located in the central or class III sub-region of MHC region \[[@B28], [@B29]\], tumor necrosis factor (TNF), an important vasoactive immuno-modulators produced by activated monocytes, is known to be up-regulated in DHF infections \[[@B30]\]. As shown in Table [1](#T1){ref-type="table"}C, polymorphism in the promoter region of the TNF-α gene, -308A allele was identified as a risk for the development of DHF in South American patients \[[@B23], [@B31]\] but not in Southeast Asian patients, despite the much larger sample size of the latter \[[@B32], [@B33]\]. This SNP was reported to be important in diabetes mellitus, asthma, and allergic rhinitis \[[@B34]\], most being associated with DHF \[[@B35]\]. Another SNP in TNF-α promoter gene, TNF-α-238A, was found to have no significant association in Vietnamese \[[@B32]\] but to be significantly increased in secondary DHF Thai patients when compared with healthy controls \[[@B33]\]. The study in Thailand has also identified an extended HLA class I, II, III (TNF, LTA) haplotype in secondary DHF patients, correlating with in vivo intracellular cytokine production in the acute viraemic phase of infection \[[@B33]\].

### c. Integrated comprehension of the MHC associations

Regarding disease severity association, some differences were observed in HLA allele frequency when comparing DHF/DSS and DF, including A\*0203, B\*52 \[[@B25]\] and DRB1\*04 \[[@B26]\] as protective factors; while B\*51 \[[@B25]\], DQB1\*0302 \[[@B35]\] and TNF-α- LTA haplotype \[[@B33]\] were noted as susceptible factors in Thai and Mexican studies. These findings suggest that DF and DHF arise from distinct immune response processes.

It has been thirty years since the first report on HLA association to dengue infection \[[@B36]\]. Many associations have been cited in the interim, but none has been replicated except for susceptible HLA- A\*24 alleles in Vietnamese \[[@B7], [@B32]\]. Moreover, the latter finding was reproduced in two different study sites in Vietnam. A study in Malaysia also found a DHF risk trend (2 fold) of A\*24 in a Chinese group \[[@B37]\]. Further subtyping, A\*2402/03/10 with histidine at codon 70, elicited a stronger significant association in the Vietnamese but not in the Malaysian population, although the latter involved a much smaller sample size. The HLA class II associations in the Kinh population, however, were not consistent with the above findings \[[@B7], [@B32]\].

2.2 Non MHC genes
-----------------

Studies on the association between susceptibility to DI and polymorphic non-HLA gene have increased recently (Table [2](#T2){ref-type="table"}).

### a. Fcγ receptor II (FcγRII, CD32)

FcγR is a widely distributed receptor for IgG subclasses and can mediate ADE in DI \[[@B38]\]. Homozygotes for the arginine variant at position 131 (R/R131) of the FcγRII gene were shown to be protective against DSS in a Vietnamese population \[[@B39]\], and also against DHF/DSS in a Cuban population with asymptomatic control \[[@B22]\]. This is the first consistent finding of host genetic analysis in DI between two very different ethnic groups from Southeast Asia and South America.

### b. Vitamin D receptor (VDR)

VDR, an immune mediator expressed on monocytes, activated B and T cells. VDR polymorphism (rs731236 T/C) analysis in a Vietnam study has shown that C allele (author named as t allele) at position 352 was resistant to DSS (p trend analysis) \[[@B39]\]. This correlates with a recent report that VDR T allele was a risk factor of type 2 diabetes with insulin secretion capacity \[[@B40]\].

### c. Dendritic Cell-Specific ICAM-3 Grabbing Nonintegrin (DC-SIGN, CD209)

DC-SIGN is an essential attachment molecule for dengue virus, expressed on the surface of DCs. The fact that DC-SIGN variant (rs4804803) protects for the supposition against DF but not DHF/DSS in three cohorts in Thailand \[[@B41]\] provided further evidence that DHF/DSS is caused by a different pathogenic mechanism than DF. This study found a decreased transcription activity of G allele versus A allele of DC- SIGN1--336, suggesting a protective effect of G allele against DF by decreased levels of the viral receptor expression of host cells. The subsequent analysis of this SNP in Brazilian population, however, did not show any association \[[@B24]\].

### d. Transporter associated with Antigen Processing (TAP)

TAP is a protein that specializes in delivering cytosolic peptides to class I molecules in the endoplasmic reticulum. TAP gene variants have shown their effect on the outcome of HPV, hepatitis C infections and autoimmune disorders \[[@B42]\]. A TAP1 polymorphism (rs1057141) study in South India showed that a heterozygous at 333 position (Ile/Val) was susceptible to DHF \[[@B42]\].

### e. Human Platelet Antigen (HPA)

HPA facilitates the interaction between platelets and endovascular wall components. HPA-1a and 1b are the 33Leu substitution for 33Pro in the b3 component of allbb3 complex. The Indian study found that HPA polymorphism associated with the severity of DI, especially heterozygous HPA 1a/1b, increases the risk of developing DSS rather than DHF \[[@B42]\]. These authors proposed that the positive correlation of TAP1 333 and HPA1 in DHF could contribute to the role of TAP in viral peptide selection and cross-reactive immune response against HPA1 antigen.

### f. Cytokine polymorphisms and dengue

Cytokine storm after T cell activation has been cited as a cause of plasma leakage \[[@B43]\]. The production of cytokines is modulated by genetic polymorphisms that are associated with susceptibility to disease \[[@B31]\]. Interleukin (IL)-10, IL-6, Transforming Growth Factor b-1 (TGFβ1), TNF-α, and IFN-γ polymorphisms that may play a role in enhancing severe dengue disease \[[@B15]\] were selected for the study.

IL-10 is a major immunomodulation mediator produced by monocyte, DCs, and T, B lymphocytes, and it is an important anti-inflammatory cytokine \[[@B44]\]. IL-10-1082 genotyping did not show any association with dengue in a Venezuelan study \[[@B31]\], but IL-10 (-1082/-819/-592) ACC/ATA haplotype was significantly associated with DHF in a Cuban study (OR = 2.54, Pc = 0.03) \[[@B23]\]. Since Il-10 was involved with TNF-α in the thrombocytopenia and hemorrhagic manifestation in dengue infection, the combination of TNF-α and IL-10 polymorphism is of interest. TNF-α-308 AA or AG and IL-10-1082 AA genotype (High TNF/low IL-10 phenotype) was more frequent in DHF patients as compared with controls (OR = 19.47) or DF (OR = 17.4); by contrast, the combination of TNF-α-308 GG and IL-10-1082 AA genotype (Low TNF/low IL-10 phenotype) was less frequent in DHF than in DF (OR = 0.275) \[[@B31]\]. Many combinations of TNF-α, IFN-γ, TGFβ1 polymorphisms and IL-10 haplotype were found to be associated with DHF as compared with controls by Perez 2010, as shown in Table [2](#T2){ref-type="table"}.

Transforming Growth Factor β-1 (TGFβ1) is a multifunctional cytokine. Chen RF *et al.* (2009) showed that individual carried TGFβ1-509 CC genotype was about twice more likely to have DHF than DF in Taiwanese. Moreover, its combination with CTLA-4 +49 G allele increased the risk of DHF and had higher DV-2 virus load than in patients with CTLA-4 +49 G allele - TGFβ1-509 T allele (p = 0.013). This finding indicated a relationship among immune gene, viral load and disease severity. Conversely, Perez *et al.* (2010) analyzed TGFβ1 at codon 25 and noted the protective effect of G allele and GG genotype against DHF.

2.3 Genome-wide study
---------------------

The results of candidate gene studies show that the sequencing data of the human genome and the HapMap project have identified millions of SNPs facilitating the implementation of GWASs.

Illumina microbead array technology was used to genotype 728 SNPs in 56 key genes of the Type I TNF response pathway and other well selected genes in a Brazilian study \[[@B24]\]. There were 58 markers with p \< 0.05, among which 11 markers are in Janus-Activated Kinase gene (JAK1), representing the largest proportion of significant markers. The most significant SNPs as well as DHF risk SNPs (rs11208534, rs2780831, rs310196) were located toward the 5' end of the JAK1 gene. Linkage disequilibrium (LD) analysis showed that the SNPs rs11208534 and rs2780831 were located in the same linkage block and that rs310196 was an independent marker (D\' rs2780831/rs11208534 = 1, rs2780831/rs310196 = 0.924, rs11208534/rs310196 = 0.856). JAK1 is a signaling protein associated with the type IFN receptor, and polymorphism in this gene may provoke the under-expression observed in severe dengue as in the expression profile of DSS patients vs. DF \[[@B45]\].

The technological development of high throughput genotyping has provided a powerful tool to examine the genetic basis of disease through GWAS. The GWAS approach, underway since 2007, has achieved success in identifying genes for many diseases like Crohn's disease, rheumatoid arthritis, type 1 and type 2 diabetes, prostate cancer macular degeneration \[[@B2]\], but little information on large scale SNP analysis of infectious diseases, including dengue, is available. With the large number of markers typed, the stringent statistical criteria necessary to minimize false positive results may be difficult to establish.

2.4 Transcript analysis
-----------------------

Understanding the pathogenesis of a complicated disease like dengue remains elusive because of the lack of a suitable animal model and the complex immune interactions in infected subjects. Gene expression studies provided an opportunity to observe the simultaneous biological relevance and interaction of genes in the disease \[[@B46]\].

The expression of mRNA transcripts and protein products of selected immune response genes has been measured in the plasma of DF and DHF patients during the acute and convalescent phases of DENV infection. High levels of soluble IL-2 receptor, IL-13, IL-18, IL-10, soluble VCAM-1, soluble CD8, macrophage inhibitory factor and TNF all correlate with disease severity in dengue and indicate a high degree of T cell activation \[[@B11], [@B30], [@B47], [@B48], [@B49]\].

2.5 Genome expression
---------------------

The development of genomics technology, microarray and high throughput quantitative PCR have revolutionized the way we study gene expression modification on a large scale and look for each change that could be important in the pathogenic process. Information from this high-throughput screening of whole transcriptomes requires careful confirmation at the phenotype level.

Host gene expression was deciphered in cells infected with DENV in vitro \[[@B50], [@B51]\] and subsequently in patients \[[@B45], [@B51], [@B52], [@B53], [@B54]\] (Table [3](#T3){ref-type="table"}). These studies mainly tried to distinguish the DSS from DF or DHF grades I/II patients (uncomplicated dengue) by comparing whole blood transcription profiles of the acute stage with those of the convalescent stage, and the healthy controls. Despite the limited sample number, the studies revealed many upregulated genes, and the host response pathways during dengue infection were elucidated by the functional studies that ensured. Gene expression profile in the early samples suggested that the innate immune response, endoplasmic reticulum (ER) stress response, cellular mitotic activity, B cell activation, innate immune response, apoptosis and oxygen transport, and ubiquitin proteasome dominated in DV- infection \[[@B45], [@B51]\].The most important findings were the less abundant transcriptions among DSS-gene signature than in those with less-severe dengue at the time of cardiovascular decompensation of both innate and acquired immune responses including T, NK cell response \[[@B52], [@B53]\], IFN-stimulated genes (ISGs) \[[@B45]\], and type I IFN pathway \[[@B9], [@B45], [@B51]\].

Considering that early host responses may reflect components of the disease pathogenesis, Tolfvenstam *et al.* preferred to focus on disease timing rather than disease severity by comparing dengue infection vs. non-dengue infection groups. They observed a strong activation of the innate immune response (chemokines CCL2 (MCP-1), CCL8 (MCP-2), CXCL10, (IP-10) and CCL3 (MIP-1α)) in the early dengue fever phase (before 72 h of fever), while the adaptive immune response, biosynthesis and metabolism dominated in the defervescence phase (day 4--7 of fever).

Again, the expression profiles are so variable that it may be difficult to reach a consensus and may even cause controversy. Some authors have highlighted the importance of timing in the course of dengue disease and suggested that the change in DSS transcription profile may occur earlier than clinical manifestations \[[@B9]\]. Devignot *et al.* concluded that a shift from DSS to uncomplicated transcriptional profile may occur within a very short time by showing that DSS samples at three days after shock exhibited a profile very close to uncomplicated dengue \[[@B53]\].

3. Conclusion
=============

Taken together, these studies reveal that associations between host genetics, DV, and clinical outcome are complex. The question of how many genes contributes to dengue susceptibility, how they interact to cause severe manifestations, and the extent to which the pathogenesis mechanism might be genetically predicted remains unknown. It is still a challenge to identify appropriate epitopes for vaccines, and further exploration is needed to identify specific medicine candidates.

Many essential issues will exert an impact on future study design, including uniform case definition, adequate sample size, quality control in typing technique, and statistical analysis method with locus-wise correction of p value. The associations should also be verified subsequently by well-designed functional studies.

###### 

Association of classical class I and II HLA polymorphism and dengue

  A. Cases vs. healthy controls                                                                                                                        
  ------------------------------- ----- ------------ ------------------- ----- ------- -------------- ---------- ---------- -------------------------- ----
  Susceptible                                                                                                                                          
   A\*0203                        2nd   DV-1         DF (49)             140   2.65    1.14--46.12    0.02       ns         Thai                       25
   A\*0203                        2nd   DV-3         DF (26)             140   3.4     1.61--12.03    \<0.0005   0.012      Thai                       25
   A\*0203                        2nd   all          DF (106)            140   3.09    1.59--6.02     \<0.0005   0.012      Thai                       25
   B\*52                          2nd   DV-2         DF (17)             140   24.91   4.61--150.14   \<0.0001   \<0.0001   Thai                       25
   B\*52                          2nd   --           DF (106)            140   5.83    1.48--26.80    0.0067     0.027      Thai                       25
   DQB1\*01                       --    --           DF (23)             34    3.12    0.09--10.9     0.04       ns         Mexican                    35
   DQB1\*0202                     --    --           DF (23)             34    7.00    1.11--73.8     0.012      ns         Mexican                    35
   DQ1                            --    --           DF (64)             201   2.4     2.4            \<0.01     0.021      Brazilian                  55
   A\*24, codon 70 histidine      --    --           DHF (59)            200   2.02    1.01--3.95     0.038      --         Vietnamese, VL 04-05       7
   A\*24, codon 70 histidine      --    --           DHF (117)           250   1.75    1.02--2.98     0.033      --         Vietnamese, HCMC           7
   A\*0207                        2nd   DV-1         DHF/DSS (32)        140   2.73    1.03--7.18     0.043      ns         Thai                       25
   A\*0207                        2nd   DV-2         DHF/DSS (36)        140   2.64    1.03--6.70     0.041      ns         Thai                       25
   A\*0207                        2nd   DV-1, DV-2   DHF/DSS (103)       140   2.68    1.26--5.72     0.0084     ns         Thai                       25
   A\*0207                        2nd   All          DHF/DSS (103)       140   2.35    1.19--4.68     0.012      ns         Thai                       25
   A\*03                          --    --           DHF/DSS (51)        95    5.23    1.19--23.02    0.015      ns         Malay, Chinese, Indian     37
   B\*13                          --    --           DHF/DSS (19)        95    --      --             0.049      ns         Malay                      37
   B\*51                          2nd   All          DHF/DSS (103)       140   4.11    1.44--12.28    0.0052     0.021      Thai                       25
   B\*51                          2nd   DV-1         DHF/DSS (32)        140   4.14    1.0--16.85     0.049      ns         Thai                       25
   B\*53                          --    --           DHF/DSS (51)        95    --      --             0.042      ns         Malay, Chinese, Indian     37
   A\*24                          --    --           DHF/DSS (309)       251   1.54    1.05--2.25     0.021      --         Vietnamese                 32
   A\*02                          2nd   --           DSS (41)            138   --      --             0.047      --         Thai                       36
   A\*24, codon 70 histidine      --    --           DSS (152)           250   1.89    1.16--3.09     0.008      --         Vietnamese, HCM            7
   A\*24, codon 70 histidine      --    --           DSS (170)           200   1.7     1.04--2.79     0.03       --         Vietnamese, VL 02-03       7
   A\*24, codon 70 histidine      --    --           DSS (96)            200   2.09    1.18--3.70     0.0075     --         Vietnamese, VL 04-05       7
   B blank                        2nd   --           DSS (41)            138   --      --             \<0.02     --         Thai                       36
   A\*31                          --    DV-2         DF, DHF/DSS (120)   189   7.6     2.3--27.7      \<0.0001   0.0002     Cuban                      27
   B\*15                          --    DV-2         DF, DHF/DSS (120)   189   4.46    1.96--10.29    \<0.0001   0.0002     Cuban                      27
   B\*51                          2nd   DV-3         DF, DHF/DSS (51)    140   4.16    1.22--14.45    0.018      ns         Thai                       25
  Resistant                                                                                                                                            
   DRB1\*11                       --    --           DF (47)             34    0.09    0--0.64        0.003      0.03       Mexican                    26
   DQB1\*0302                     --    --           DF (23)             34    0.23    0.06--0.84     0.011      ns         Mexican                    35
   DRB1\*0901                     1st   --           DHF (59)            200   0.22    0.02--0.95     0.027      0.3        Vietnamese, VL 04-05       7
   A\*33                          --    --           DHF/DSS (309)       251   0.56    0.34--0.93     0.014      --         Vietnamese                 32
   B\*18                          --    --           DHF/DSS (51)        95    --      --             0.017      ns         Malay, (Chinese, Indian)   37
   B\*13                          2nd   --           DSS (41)            138   --      --             --         --         Thai                       36
   DRB1\*0901                     --    --           DSS (170)           200   0.56    0.34--0.93     0.018      0.2        Vietnamese, VL 02-03       7
   DRB1\*0901                     --    --           DSS (96)            200   0.37    0.18--0.72     0.0018     0.02       Vietnamese, VL 04-05       7
   B\*35                          --    --           DF, DHF/DSS (39)    34    0.12    0.037--0.39    \<0.0001   0.01       Mexican                    35
   DRB1\*04                       2nd   DV-2         DF, DHF/DSS (77)    189   0.19    0.05--0.63     0.001      0.01       Cuban                      27
   DRB1\*07                       --    DV-2         DF, DHF/DSS (120)   189   0.25    0.11--0.55     0.0001     0.0004     Cuban                      27

  B. DHF/DSS vs. DF                                                                             
  ------------------- ----- ---- ----- ----- ------ ------------- --------- --------- --------- ----
  Susceptible                                                                                   
   B\*48              2nd   --   132   169   --     --            \<0.001   \<0.035   Thai      33
   B\*51              2nd   --   103   106   3.07   1.07--9.22    0.036     ns        Thai      25
   DQB1\*0302         --    --   16    23    5.02   1.05--25.34   0.018     ns        Mexican   35
  Resistant                                                                                     
   A\*0203            2nd   --   103   106   0.41   0.2--0.82     0.01      ns        Thai      25
   B\*52              2nd   --   103   106   0.08   0.00--0.59    0.049     0.02      Thai      25
   DRB1\*04           --    --   34    47    0.31   0.11--0.85    0.011     ns        Mexican   26

  C. Class III                                                                                                                             
  ------------------------------------ ----- ----------- --------------- ---------- --------- ---------------- ---------- -------- ------- ----
  TNF-α (-308 -238 +488) GAG           2nd   --          DHF/DSS (132)   NC (143)   2.38      1.01--5.7        0.03       ns       Thai    33
  TNF-α-308 A                          --    DV-1/DV-2   DSS (43)        NC (99)    3.51      1.77--7.00       0.00006    0.0001   Cuban   23
  TNF-α-308AG                          --    DV-1/DV-2   DSS (43)        NC (99)    4.07      1.45--11.43      0.005      0.013    Cuban   23
  TNF-α (-308/-238/+488) GGA           1st   --          DHF/DSS (10)    DF (59)    12.2 \*   1.73--86.1\*\*   0.019      ns       Thai    33
  TNF-α (-308/-238/+488) GAG           2nd   --          DHF/DSS (132)   DF (169)   4.13      1.59--11.17      \< 0.001   0.022    Thai    33
  TNF-1,4 LTA-1,3 &TNF-1,4 LTA-3,3     2nd   --          DHF/DSS (129)   DF (163)   --        --               \<0.001    0.014    Thai    33
  TNF-238A &LTA (+249/+365/+720) AGC   --    --          DHF (129)       DF (163)   4         1.4--11.7        0.003      0.034    Thai    33
  TNF-α (-308 -238 +488) GGA           1st   --          DF (59)         NC (143)   0.24      0.04--1.15       0.046      ns       Thai    33
  TNF-α-308 GG                         --    DV-1/DV-2   DSS (43)        NC (99)    0.35      0.16--0.75       0.007      0.001    Cuban   23

Note: DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome. 1st: Primary infection, 2nd: Secondary infection.

DV: dengue virus (serotype). OR: Odds ratio, 95% CI: 95% confidence intervals, Pc: corrected p, ns: non significant, Author data: \*0.08 ; \*\*0.01--0.76

###### 

Non-HLA polymorphism and dengue

  A. Cases vs. healthy controls                                                                                                                                     
  ------------------------------------------------------- ---- ----------- --------------- ---------- -------- -------------- ---------- ------- ------------------ ----
  Susceptible                                                                                                                                                       
   IL-10 (-1082/-819/-592) ACC/ATA                        --   DV-1/DV-2   DSS (43)        NC (99)    2.54     1.12--5.73     0.02       0.03    Cuban              23
   TNFα -308A & INFγ 874T                                 --   DV-1/DV-2   DSS (43)        NC (99)    3,968    1.48--10.62    0.004      0.009   Cuban              23
   TNFα -308A & IL-10 (-1082/-819/-592) ACC/ATA           --   DV-1/DV-2   DSS (43)        NC (99)    10,057   2.03--49.72    0.001      0.003   Cuban              23
   TNFα -308A & IL-10 (-1082/-819/-592) ACC or ATA        --   DV-1/DV-2   DSS (43)        NC (99)    3,924    1.78--8.64     0.0004     0.001   Cuban              23
   IFN-γ & IL10 (-1082/-819/-592) ACC/ATA                 --   DV-1/DV-2   DSS (43)        NC (99)    17,306   2.05--145.73   0.001      0.002   Cuban              23
   TNFα-308A & TGF1 codon 25C                             --   DV-1/DV-2   DSS (43)        NC (99)    5,333    1.50--18.89    0.005      0.013   Cuban              23
   TNFα-308A & INFγ + 874T & IL10 (-1082/-819/-592) ATA   --   DV-1/DV-2   DSS (43)        NC (99)    9,162    1.81--46.31    0.002      0.006   Cuban              23
   DC-SIGN1-336G                                          --   --          DHF/DSS (454)   NC (696)   0.204    --             2×10^−6^   --      Thai (3 cohorts)   41
   TAP1 333 Val & HPA 1b                                  --   --          DHF/DSS (107)   NC (100)   --       --             \<0.05     --      South Indian       42
   TNF-308 AA or AG & IL-10-1082 AA                       --   --          DHF (25)        NC (46)    19.47    1--378.2       0.013      ns      Venezuelan         31
   TAP1 333 Ile/Val                                       --   --          DHF (75)        NC (100)   2.7      1.46--5.01     0.005      --      South Indian       42
   FcγRIIa H/H131                                         --   DV-4        DF (68)         SI (42)    4,425    1.10--20.52    0.016      --      Cuban              22
   HPA1 1a/1b                                             --   --          DSS (32)        DHF (75)   4.75     --             0.003      --      South Indian       42
   FcγRIIa H/H131                                         --   DV-4        DSS (29)        SI (42)    10.56    2.33--54.64    0.00018    --      Cuban              22
   TNF-308 AA or AG & IL-10-1082 AA                       --   --          DHF (25)        DF (41)    17.4     0.89--338      0.017      ns      Venezuelan         31
  Resistant                                                                                                                                                         
   Vitamin D receptor 352 C                               --   --          DSS (352)       NC (251)   --       --             0.033      --      Vietnamese         32
   TGFβ1 codon25 G allele                                 --   DV-1/DV-2   DSS (43)        NC (99)    0.38     0.21--0.69     --         0.002   Cuban              23
   TGFβ1 codon25 GG                                       --   DV-1/DV-2   DSS (43)        NC (99)    0.34     0.15--0.76     --         0.01    Cuban              23
   TNFα-308G & INFγ + 874A & TGFβ1 codon25 GG             --   DV-1/DV-2   DSS (43)        NC (99)    0.291    0.09-0.89      0.025      0.044   Cuban              23

  B. DHF/DSS vs. DF                                                                                                                 
  ------------------------------ ---- ------ --------------- ---------- ------- -------------- ------------ ---- ------------------ ----
  Susceptible                                                                                                                       
   TAP1 333 Ile/Val              --   --     DHF (75)        DF (91)    2.58    --             0.007        --   South Indian       42
   HPA 1a/1a                     --   --     DHF (75)        DF (91)    1.93    --             0.006        --   South Indian       42
   HPA 2a/2b                     --   --     DHF (75)        DF (91)    2.8     --             0.007        --   South Indian       42
   TGFβ1-509 CC                  --   DV-2   DHF (100)       DF (150)   1.94    1.04-3.61      0.034        --   Taiwanese          49
   CTLA-4 +49 G & TGFβ1-509 CC   --   --     DHF (100)       DF (150)   2.10    1.07--4.09     0.028        --   Taiwanese          49
   JAK1 rs11208534 (TT)          --   --     DHF (50)        DF/ SI     5.19    2.13--12.66    \<0.05       --   Brazilian          24
  Resistant                                                                                                                         
   DC-SIGN1-336G                 --   --     DHF/DSS (454)   DF (152)   5.84    2.77--12.31    1.4×10^−7^   --   Thai (3 cohorts)   41
   TNF-308 GG & IL10-1082 AA     --   --     DHF (25)        DF (41)    0.275   0.094--0.805   0.023        ns   Venezuelan         31
   JAK1 rs310196 (TT)            --   --     DHF (50)        DF/ SI     0.3     0.15--0.57     \<0.05       --   Brazilian          24

Note: DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome. 1st: Primary infection, 2nd: Secondary infection. DV: dengue virus (serotype). OR: Odds ratio, 95%CI: 95% confidence intervals, Pc: corrected p, ns: non-significant

###### 

Genome expression of dengue infection

      Population            Subjects                            Sampling time                                  Genes (abundant) expression associated with DI                                                                                                            Gene expression associated with DSS                                                                                                                       Reference
  --- --------------------- ----------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  1   Vietnamese adults     6 DSS: 8 non-DSS: 4 control (2nd)   \- Admission - A month later                   The ER stress response, cellular mitotic activity, B cell activation, innate immune response, apoptosis & oxygen transport.                               Increased B cell activation. Decreased ISGs, IFN-regulated, immune response.                                                                              45
                                                                                                                                                                                                                                                                                                                                                                                                                                   
  2   Singapore adults      10 DF: 10 non-dengue                \- before day3 - day 7 - 3--4 weeks later      NF-~K~B (IP-10), type I IFN (I-TAC) and ubiquitin proteasome.                                                                                             NA                                                                                                                                                        51
                                                                                                                                                                                                                                                                                                                                                                                                                                   
  3   Thai children         1 DSS: 3 DHF : 5 DF                 \- Admission - A month later                   Metabolic and signal transduction, IFN-inducible and IFN-induced genes.                                                                                   Decreased both innate & acquired immune responses: cytokine/chemokine signaling molecule production, T and B cell activation, & killer cell activation.   52
                                                                                                                                                                                                                                                                                                                                                                                                                                   
  4   Vietnamese (adult?)   9 DSS: 9 non-DSS                    \- Day 4 - A month later                       Oxidative metabolism, interferon signaling, protein ubiquitination, apoptosis, and cytokines.                                                             Decreased apoptotic and type I IFN pathways.                                                                                                              9
                                                                                                                                                                                                                                                                                                                                                                                                                                   
  5   Cambodian children    19 DSS: 13 DHF: 16 DF               --                                             --                                                                                                                                                        Decreased T, NK lymphocyte responses, increased anti-inflammatory, repair/remodeling transcripts, innate immunity, inflammation and lipid metabolism.     53
                                                                                                                                                                                                                                                                                                                                                                                                                                   
  6   Singapore adults      31 DI: 26 non- den                  \- before day3 - day 4--7 - 3--4 weeks later   Innate immune response: IFN-signaling, pathogen recognition, and complement activation, biosynthesis, metabolism. Decreased T cell associated pathways.   NA                                                                                                                                                        54

Note: DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, DI: dengue infection, 2nd: Secondary infection, ER: endoplasmic reticulum, ISGs: IFN-stimulated genes, NA: not applicable
